TSL2109 capsules approved for clinical trials
October 26, 2025
Source: drugdu
165
recently announced that its wholly-owned subsidiary, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., received the "Notice of Approval for Clinical Trial of Drugs" from the National Medical Products Administration (NMPA) for TSL2109 Capsules for the treatment of advanced solid tumors. TSL2109 Capsules, jointly developed by Jiangsu Diyi and China Pharmaceutical University, is a novel dual-target small molecule inhibitor. It selectively inhibits the downstream signaling pathways of both targets, arrests the tumor cell cycle, and induces apoptosis, achieving a synergistic killing effect. Currently, no similar dual-target drugs have entered clinical trials outside of China .
As a traditional pharmaceutical company specializing in traditional Chinese medicine and chemical drugs, Tasly has been actively transforming its focus into innovative drugs in recent years. TSL2109 Capsule is a dual-target small molecule inhibitor with a novel structure, a first of its kind globally. However, investors should be aware of the high risks of drug development.
Source: https://wap.eastmoney.com/a/202509243522600041.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
